|

Control treatment arm Clinical Trials

1 actively recruiting trial

Also known as: Endocrine therapy of physician's choice[TPC]

Pipeline

Phase 2: 1

Top Sponsors

  • Yonsei University1

Indications

  • Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)1
  • Breast Cancer1
  • Cancer1

Other1 trial

Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.